Year: 2020
Type: dissertation
Abstract: The incretin effect is essential for glucose homeostasis. Glucagon-like peptide 1 (GLP-1) based drugs, like liraglutide, and GLP-1 C-terminal fragment, GLP-128-36, have garnered attention for their weight lowering effects. However, their “preventative effects” on obesity development have not been explored in animal models. To investigate this, male C57BL/6J mice were given liraglutide or GLP-128-36 after 10 days of HFD or LFD continued for 8 weeks, with injections 6 times per week. The daily body weight and other metabolic parameters were assessed. Liraglutide moderately reduced body weight gain, fasting blood glucose and triglyceride (TG) levels, and improved glucose disposal as well as insulin-stimulated hepatic Akt (Ser473) phosphorylation in HFD fed mice and moderately increased β-catenin (Ser675) phosphorylation in INS-1 cells. Also, the body weight gain lowering effect of liraglutide gradually diminished with continued treatment. Altogether, the findings indicate that liraglutide, but not GLP-128-36, has a moderate preventative effect on obesity development.
Source: TSpace (University of Toronto)
Author: Manroop Khroud
Institution: University of Toronto
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3162981282
